Firebrick Pharma (ASX:FRE) secured a AU$1.1 million investment from Pharma Nutria, part of the SV More Group of Companies, which includes its Philippine licensing partner, SV More Pharma, according to a Tuesday filing with the Australian bourse.
Pharma Nutria is acquiring 11.6 million shares in the company at AU$0.095 apiece, subject to a voluntary escrow of 12 months, the filing said.
Proceeds will be used to cover marketing expenses for Nasodine nasal spray in Singapore, new product development for all markets, and other operational working capital, according to the filing.
Firebrick Pharma shares rose nearly 9% in morning trade Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.